SPARC.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:57):

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally...

Stats
Šios dienos apimtis	4.68M
Vidutinė apimtis	511 527
Rinkos kapitalizacija	79.35B
EPS	INR0 ( 2024-02-04 )
Kita pelno data	( INR0 ) 2024-05-19
Last Dividend	INR0 ( N/A )
Next Dividend	INR0 ( N/A )
P/E	-21.60
ATR14	INR0 (0.00%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: 0.00 (neutral)

Signal:(27.225) Neutral

Sun Pharma Advanced Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sun Pharma Advanced Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

Sun Pharma Advanced Finansinės ataskaitos

Annual	2022
Pajamos:	INR2.31B
Bruto pelnas:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Pajamos:	INR2.31B
Bruto pelnas:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Pajamos:	INR1.37B
Bruto pelnas:	INR105.52M (7.69 %)
EPS:	INR-8.24

FY	2021
Pajamos:	INR2.53B
Bruto pelnas:	INR465.55M (18.40 %)
EPS:	INR-5.77

Financial Reports:

No articles found.

Sun Pharma Advanced

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited